Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 40,313 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $49.44, for a total value of $1,993,074.72. Following the sale, the chief financial officer now owns 424,536 shares of the company’s stock, valued at approximately $20,989,059.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Kenneth Allen Myszkowski also recently made the following trade(s):
- On Monday, January 6th, Kenneth Allen Myszkowski sold 20,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total value of $1,202,200.00.
- On Friday, November 1st, Kenneth Allen Myszkowski sold 37,884 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $40.85, for a total value of $1,547,561.40.
Shares of NASDAQ ARWR opened at $40.43 on Friday. Arrowhead Pharmaceuticals Inc has a 1 year low of $12.72 and a 1 year high of $73.72. The company has a current ratio of 6.89, a quick ratio of 2.73 and a debt-to-equity ratio of 0.03. The firm’s 50-day moving average is $54.77 and its 200-day moving average is $43.41. The firm has a market capitalization of $4.18 billion, a PE ratio of 76.28 and a beta of 1.95.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.07). Arrowhead Pharmaceuticals had a return on equity of 18.21% and a net margin of 32.56%. The business had revenue of $29.46 million for the quarter, compared to analyst estimates of $36.63 million. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals Inc will post -0.17 earnings per share for the current fiscal year.
Several brokerages have recently weighed in on ARWR. Svb Leerink assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 21st. They set an “underperform” rating and a $32.00 target price for the company. Cantor Fitzgerald raised their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Thursday. Piper Jaffray Companies raised their target price on shares of Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, December 9th. S&P Equity Research reissued a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 26th. Finally, BidaskClub lowered shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 28th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $64.13.
A number of institutional investors have recently made changes to their positions in ARWR. Securian Asset Management Inc bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $652,000. FMR LLC increased its holdings in Arrowhead Pharmaceuticals by 38.9% during the 4th quarter. FMR LLC now owns 1,881,408 shares of the biotechnology company’s stock worth $119,338,000 after purchasing an additional 526,552 shares during the period. Eagle Asset Management Inc. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $44,658,000. Los Angeles Capital Management & Equity Research Inc. boosted its position in Arrowhead Pharmaceuticals by 4.1% during the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 103,370 shares of the biotechnology company’s stock valued at $6,557,000 after acquiring an additional 4,065 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 629,061 shares of the biotechnology company’s stock worth $39,902,000 after purchasing an additional 24,699 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.